ADVIKLA

MPS Pharma Share Price

₹3.95
10 October, 2024 23:33 BSE: 531686 NSE: ADVIKLA ISIN: INE537C01019

Start SIP in MPS Pharma

Start SIP

MPS Pharma Performance

Day Range

  • Low 0
  • High 0
₹ 3

52 Week Range

  • Low 0
  • High 0
₹ 3
  • Open Price0
  • Previous Close0
  • Volume

MPS Pharma Chart

  • Over 1 Month + 2.86%
  • Over 3 Month + 7.92%
  • Over 6 Month + 23.05%
  • Over 1 Year + 48.5%

MPS Pharma Key Statistics

MPS Pharma Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 000000
Operating Expenses Qtr Cr 000000
Operating Profit Qtr Cr 000000
Depreciation Qtr Cr 000000
Interest Qtr Cr 000000
Tax Qtr Cr 000000
Net Profit Qtr Cr 000000
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 00
Operating Expenses Annual Cr 11
Operating Profit Annual in Cr -1-1
Depreciation Cr 00
Interest Annual Cr 00
Tax Annual Cr 00
Net Profit Annual Cr -1-1
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr -1-1
Cash from Investing Activity Annual Cr 00
Cash from Financing Annual Activity Cr 11
Net Cash Flow Annual Cr 00
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 23
Fixed Assets Annual Cr 78
Total Non Current Assets Annual Cr 88
Total Current Assets Annual Cr 22
Total Assets Annual Cr 1010
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 11
ROE Annual % -42-38
ROCE Annual % -39-35
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 00
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

MPS Pharma Technicals

EMA & SMA

Current Price
₹3.95
+ 0 (0%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹3.70
  • 50 Day
  • ₹3.27
  • 100 Day
  • ₹2.75
  • 200 Day
  • ₹2.27
  • 20 Day
  • ₹3.68
  • 50 Day
  • ₹3.22
  • 100 Day
  • ₹2.63
  • 200 Day
  • ₹1.71

MPS Pharma Resistance and Support

PIVOT
₹3.95
Resistance
First Resistance 3.95
Second Resistance 3.95
Third Resistance 3.95
RSI 89.52
MFI 74.14
MACD Single Line 0.22
MACD 0.22
Support
First Support 3.95
Second Support 3.95
Third Supoort 3.95

MPS Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 2,015 201,500 100
Week 2,015 201,500 100
1 Month
6 Month 1,291 129,076 100

MPS Pharma Result Highlights

MPS Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

MPS Pharma Corporate Action

Date Purpose Remarks
2024-08-13 Quarterly Results
2024-05-30 Audited Results
2024-03-26 Independent Director Meeting
2024-02-13 Quarterly Results
2023-11-09 Quarterly Results

MPS Pharma FAQs

What is Share Price of MPS Pharma ?

MPS Pharma share price is ₹3 As on 10 October, 2024 | 23:19

What is the Market Cap of MPS Pharma ?

The Market Cap of MPS Pharma is ₹7.5 Cr As on 10 October, 2024 | 23:19

What is the P/E ratio of MPS Pharma ?

The P/E ratio of MPS Pharma is -8.7 As on 10 October, 2024 | 23:19

What is the PB ratio of MPS Pharma ?

The PB ratio of MPS Pharma is 3.8 As on 10 October, 2024 | 23:19

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23